^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD52 inhibitor

    Related drugs:
    1m
    T-PLL: Observatory of Prolymphocytic Leukemia T (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    1m
    Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression. (PubMed, Oncogenesis)
    Furthermore, by systematically separating expression sources, our clinical validation established that tumor-derived CD52 is a prognostic indicator of poor patient survival. These findings characterize CD52 as a critical, tumor-intrinsic driver of PDAC progression, highlighting its value as a prognostic biomarker and a therapy target in combination with immune checkpoint blockade to overcome innate therapeutic resistance in PDAC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD52 (CD52 Molecule)
    2ms
    Targeting the cytokine storm: new therapies in the treatment of paediatric haemophagocytic lymphohistiocytosis. (PubMed, Expert Rev Clin Immunol)
    Emapalumab, alemtuzumab and ruxolitinib show promising results, however widespread use is limited by small, non-randomized trials in a heterogenous population. Further international collaborative efforts to develop clinical trials to put conventional chemotherapy treatments head-to-head with these newer therapies is critical for advancement of these agents.
    Review • Journal
    |
    IFNG (Interferon, gamma)
    |
    Jakafi (ruxolitinib) • Campath (alemtuzumab)
    2ms
    A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients (clinicaltrials.gov)
    P3, N=10, Completed, Northwestern University | N=40 --> 10 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    |
    Campath (alemtuzumab)
    2ms
    CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review. (PubMed, Am J Clin Pathol)
    CD48 expression is diminished compared with normal background T cells in most cases of T-ALL at diagnosis and posttherapy, whereas it was typically retained in mature T-cell/natural killer-cell neoplasms. While CD48 levels may fluctuate after chemotherapy in T-ALL, reduced CD48 can be used as a marker of immaturity in most MRD cases. Potential confounders in the assessment of CD48 include alemtuzumab therapy and the presence of GPI-deficient populations.
    Retrospective data • Journal
    |
    CD48 (CD48 Molecule)
    |
    Campath (alemtuzumab)
    2ms
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    2ms
    LEMTRADA Pregnancy Registry in Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=42, Completed, Genzyme, a Sanofi Company | Terminated --> Completed
    Trial completion
    |
    Lemtrada (alemtuzumab)
    3ms
    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Heart, Lung, and Blood Institute (NHLBI)
    New P1/2 trial
    |
    Campath (alemtuzumab) • Orencia (abatacept)
    4ms
    First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. (PubMed, J Clin Oncol)
    IL15-CIK monotherapy is feasible and safe and demonstrates promising relapse-preventive activity after hematopoietic stem-cell transplantation. Clinical outcomes are strongly influenced by disease burden at treatment initiation and previous serotherapy, supporting optimized patient selection and timing in future post-transplant immunotherapeutic strategies.
    P1 data • Journal • First-in-human
    |
    IL15 (Interleukin 15)
    |
    Campath (alemtuzumab)
    4ms
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    5ms
    ADAs to Alemtuzumab (clinicaltrials.gov)
    P=N/A, N=15, Completed, Queen Mary University of London | Active, not recruiting --> Completed
    Trial completion
    |
    Lemtrada (alemtuzumab)